Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding. A European perspective;Recommandations européennes pour l'utilisation du facteur VII activé recombinant comme thérapeutique adjuvante du saignement majeur

Annales Francaises d'Anesthesie et de Reanimation

Volumn 26, Issue 2, 2007, Pages 145-156

  Vincent, J L ^a   Rossaint, R ^b   Riou, B ^c   Ozier, Y ^d   Zideman, D ^e   Spahn, D R ^f  

^a ERASME HOSPITAL   (Belgium)

^b hôpital universitaire   (Germany)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^d université Paris Cité   (France)

^e IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^f UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Bleeding; Clotting factors; Recombinant activated VII factor; Recommendation

Indexed keywords

BLOOD CLOTTING FACTOR; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ARTICLE; BLEEDING; BLOOD TRANSFUSION; BLUNT TRAUMA; CONSENSUS DEVELOPMENT; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG MONITORING; DRUG USE; ELECTIVE SURGERY; EUROPE; EVIDENCE BASED MEDICINE; HEART SURGERY; HUMAN; LIVER CIRRHOSIS; LIVER DISEASE; LIVER SURGERY; PENETRATING TRAUMA; POSTPARTUM HEMORRHAGE; PRACTICE GUIDELINE; THROMBOEMBOLISM; TREATMENT INDICATION;

EID: 33846926754     PISSN: 07507658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.annfar.2006.10.008     Document Type: Article

References (71)

1. Hoyt D.B. A clinical review of bleeding dilemmas in trauma. Semin. Hematol. 41 1 Suppl 1 (2004) 40-43
2. Potenza B., Hoyt D., Coimbra R., Fortlage D., Holbrook T., and Hollingsworth-Fridlund P. Trauma Research and Education Foundation. The epidemiology of serious and fatal injury in San Diego County over an 11-year period. J. Trauma 56 (2004) 68-75
3. Sauaia A., Moore F., and Moore E. Epidemiology of trauma deaths: A reassessment. J. Trauma 38 (1995) 185-193
4. D'Amico G., and de Franchis R. Cooperative-Study Group. Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators. Hepatology 38 (2003) 599-612
5. Hall T.S., Brevetti G.R., Skoultchi A.J., Sines J.C., Gregory P., and Spotnitz A.J. Re-exploration for hemorrhage following open heart surgery differentiation on the causes of bleeding and the impact on patient outcomes. Ann. Thorac. Cardiovasc. Surg. 7 (2001) 352-357
6. Spahn D.R., and Rossaint R. Coagulopathy and blood components transfusion in trauma. Br. J. Anaesth. 95 (2005) 130-139
7. Lynn M., Jeroukhimov I., Klein Y., and Martinowitz U. Updates in the management of severe coagulopathy in trauma patients. Intensive Care Med. 28 Suppl 2 (2002) S241-S247
8. Hoyt D.B., Bulger E.M., Knudson M.M., Morris J., Ierardi R., Sugerman H.J., et al. Death in the operating room: an analysis of a multi-center experience. J. Trauma 37 (1994) 426-432
9. Claridge J.A., Sawyer R.G., Schulman A.M., McLemore E.C., and Young J.S. Blood transfusions correlate with infections in trauma patients in a dose-dependent manner. Am. Surg. 68 (2002) 566-572
10. Moore F.A., Moore E.E., and Sauaia A. Blood transfusion. An independent risk factor for postinjury multiple organ failure. Arch. Surg. 132 (1997) 620-624
11. Malone D.L., Dunne J., Tracy J.K., Putnam A.T., Scalea T.M., and Napolitano L.M. Blood transfusion, independent of shock severity, is associated with worse outcome in trauma. J. Trauma 54 (2003) 898-905
12. Vincent J.L., Baron J.F., Reinhart K., Gattinoni L., Thijs L., Webb A., et al. Anemia and blood transfusion in critically ill patients. JAMA 288 (2002) 1499-1507
13. Erhardtsen E. Ongoing NovoSeven trials. Intensive Care Med. 28 Suppl 2 (2002) S248-S255
14. Hoffman M. A cell-based model of coagulation and the role of factor VIIa. Blood Rev. 17 Suppl 1 (2003) S1-S5
15. Hoffman M., and Monroe D.M. The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis. Dis. Mon. 49 (2003) 14-21
16. Gabriel D.A., Li X., Monroe D.M., and Roberts H.R. Recombinant human factor VIIa (rFVIIa) can activate factor FIX on activated platelets. J. Thromb. Haemost. 2 (2004) 1816-1822
17. Toschi V., Gallo R., Lettino M., Fallon J.T., Gertz S.D., Fernandez-Ortiz A., et al. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation 95 (1997) 594-599
18. Goodnough L.T., Lublin D.M., Zhang L., Despotis G., and Eby C. Transfusion medicine service policies for recombinant factor VIIa administration. Transfusion 44 (2004) 1325-1331
19. Dellinger R.P., Carlet J.M., Masur H., Gerlach H., Calandra T., Cohen J., et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit. Care Med. 32 (2004) 858-873
20. Watts D.D., Trask A., Soeken K., Perdue P., Dols S., and Kaufmann C. Hypothermic coagulopathy in trauma: effect of varying levels of hypothermia on enzyme speed, platelet function, and fibrinolytic activity. J. Trauma 44 (1998) 846-854
21. DeLoughery T.G. Coagulation defects in trauma patients: etiology, recognition, and therapy. Crit. Care Clin. 20 (2004) 13-24
22. Meng Z.H., Wolberg A.S., Monroe D.M., and Hoffman M. The effect of temperature and pH on the activity of factor VIIa: implications for the efficacy of high-dose factor VIIa in hypothermic and acidotic patients. J. Trauma 55 (2003) 886-891
23. Luna G., Maier R., and Pavlin G. Incidence and effect of hypothermia in seriously injured patients. J. Trauma 27 (1987) 1014-1018
24. Vivien B., Langeron O., Morell E., Devilliers C., Carli P.A., Coriat P., et al. Early hypocalcemia in severe trauma. Crit. Care Med. 33 (2005) 1946-1952
25. Stehling L.C. Task Force. Practice guidelines for blood component therapy: a report by the American Society of Anesthesiologists Task Force on Blood Component Therapy. Anesthesiology 84 (1996) 732-747
26. Ciaverella D., Reed R.L., Counts R.B., Baron L., Pavlin E., Heimbach D.M., et al. Clotting factor levels and the risk of diffuse microvascular bleeding in the massively transfused patient. Br. J. Haematol. 67 (1987) 365-368
27. Biggs R., and MacFarlane R.G. Human blood coagulation and its disorders, 3rd ed (1962), Blackwell, Oxford
28. Boffard K.D., Riou B., Warren B., Iau P., Rizoli S.B., Rossaint R., et al. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients. Two parallel randomized, placebo-controlled, double-blind clinical trials. J. Trauma 59 (2005) 8-15
29. Martinowitz U., Kenet G., Segal E., Luboshitz J., Lubetsky A., Ingerslev J., et al. Recombinant activated factor VII for adjunctive hemorrhage control in trauma. J. Trauma 51 (2001) 431-438
30. Martinowitz U., and Michaelson M. The Israeli Multidisciplinary rFVIIa Task Force. Guidelines for the use of recombinant activated factor VII (rFVIIa) in uncontrolled bleeding: a report by the Israeli Multidisciplinary rFVIIa Task Force. J. Thromb. Haemost. 3 (2005) 640-648
31. Dutton R.P., McCunn M., Hyder M., D'Angelo M., O'Connor J., Hess J.R., et al. Factor VIIa for correction of traumatic coagulopathy. J. Trauma 57 (2004) 709-718
32. Harrison T.D., Laskosky J., Jazaeri O., Pasquale M.D., and Cipolle M. "Low-dose" recombinant activated factor VII results in less blood and blood product use in traumatic hemorrhage. J. Trauma 59 1 (2005) 50-54
33. Klitgaard T., Tabanera y Palacios R., Boffard K.D., Iau P.T.C., Warren B., Rizoli S., et al. Pharmacokinetics of recombinant activated factor VII in trauma patients with severe bleeding. Crit. Care 10 (2006) R104
34. Bernstein D.E., Jeffers L., Erhardtsen E., Reddy K.R., Glazer S., Squiban P., et al. Recombinant factor VIIa corrects prothrombin time in cirrhotic patients: a preliminary study. Gastroenterology 113 (1997) 1930-1937
35. Bosch J., Thabut D., Bendtsen F., D'Amico G., Albillos A., Gonzalez Abraldes J., et al. Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial. Gastroenterology 127 (2004) 1123-1130
36. Moscardo F., Perez F., De La Rubia J., Balerdi B., Lorenzo J.I., Senent M.L., et al. Successful treatment of severe intraadominal bleeding associated with disseminated intravascular coagulation using recombinant activated factor VII. Br. J. Haematol. 113 (2001) 174-176
37. Segal S., Shemesh I.Y., Blumenthal R., Yoffe B., Laufer N., Ezra Y., et al. Treatment of obstetric hemorrhage with recombinant activated factor VII (rFVIIa). Arch. Gynecol. Obstet. 268 (2003) 266-267
38. Bouwmeester F.W., Jonkhoff A.R., Verheijen R.H., and van Geijn H.P. Successful treatment of life-threatening postpartum hemorrhage with recombinant activated factor VII. Obstet. Gynecol. 101 (2003) 1174-1176
39. Boehlen F., Morales M.A., Fontana P., Ricou B., Irion O., and de Moerloose P. Prolonged treatment of massive postpartum haemorrhage with recombinant factor VIIa: case report and review of the literature. BJOG 111 (2004) 284-287
40. Ahonen J., and Jokela R. Recombinant factor VIIa for life-threatening post-partum haemorrhage. Br. J. Anaesth. 94 (2005) 592-595
41. ®) in the management of intractable post-surgical intraabdominal haemorrhage. Br. J. Haematol. 107 (1999) 677-678
42. Laffan M.A., and Cummins M. Recombinant factor VIIa for intractable surgical bleeding [Abstract]. Br. J. Am. Soc. Hematol. 96 (2000) 85
43. Vlot A.J., Mackaay A.J.C., Kramer M.H.H., and Gaillard C.A.J.M. Treatment of a severely bleeding patient without preexisting coagulopathy with activated recombinant factor VII. Am. J. Med. 108 (2000) 421-422
44. Liem K.S.A.E., Biesma D.H., Ernst S.M.P.G., and Schepens M.A.A.M. Recombinant activated factor VII for false aneurysms in patients with normal haemostatic mechanisms. Thromb. Haemost. 82 (1999) 150-151
45. Svartholm E., Annerhagen V., and Lanne T. Treatment of bleeding in severe necrotizing pancreatitis with recombinant factor VIIa. Anesthesiology 96 (2002) 1528
46. Ng H.J., Koh L.P., and Lee L.H. Successful control of postsurgical bleeding by recombinant factor VIIa in a renal failure patient given low molecular weight heparin and aspirin. Ann. Hematol. 82 (2003) 257-258
47. Gielen-Wijffels S.E., van Mook W.N., Van der Geest S., and Ramsay G. Successful treatment of severe bleeding with recombinant factor VIIa after kidney transplantation. Intensive Care Med. 30 (2004) 1232-1234
48. Danilos J., Goral A., Paluszkiewicz P., Przesmycki K., and Kotarski J. Successful treatment with recombinant factor VIIa for intractable bleeding at pelvic surgery. Obstet. Gynecol. 101 (2003) 1172-1173
49. Conesa V., Navarro-Ruiz A., Borras-Blasco J., Mompel A., Gomez A., and Gonzalez M. Recombinant factor VIIa is an effective therapy for abdominal surgery and severe thrombocytopenia: a case report. Int. J. Hematol. 81 (2005) 75-76
50. Gerlach R., Marquardt G., Wissing H., Scharrer I., Raabe A., and Seifert V. Application of recombinant activated factor VII during surgery for a giant skull base hemangiopericytoma to achieve safe hemostasis. J. Neurosurg. 96 (2002) 946-948
51. Raux M., Chiche L., Vanhille E., and Riou B. Recombinant activated factor VII to control massive postoperative bleeding after septic aortobifemoral grafting. Eur. J. Anaesthesiol. 22 (2005) 805-807
52. Diprose P., Herbertson M.J., O'shaughnessy D., and Gill R.S. Activated recombinant factor VII after cardiopulmonary bypass reduces allogenic transfusion in complex non-coronary cardiac surgery: randomized double-blind placebo-controlled pilot study. Br. J. Anaesth. 95 (2005) 596-602
53. Karkouti K., Beatioe W.S., Wijeysundera D.N., Yau T.M., McCluskey S.A., Ghannam M., et al. Recombinant factor VIIa for intractable blood loss after cardiac surgery: a propensity score-matched case-control analysis. Transfusion 45 (2005) 26-34
54. Raivio P., Suojaranta-Ylinen P., and Kuitunen A.H. Recombinant factor VIIa in the treatment of postoperative hemorrhage after cardiac surgery. Ann. Thorac. Surg. 80 (2005) 66-71
55. Hyllner M., Houltz E., and Jeppsson A. Recombinant activated factor VII in the management of life-threatening bleeding in cardiac surgery. Eur. J. Cardiothorac. Surg. 28 (2005) 254-258
56. Aggarwal A., Malkovska V., Catlett J.P., and Alcorn K. Recombinant activated factor VII (rFVIIa) as salvage treatment for intractable hemorrhage. Thromb. J. 2 (2004) 9
57. DiDomenico R.J., Massad M.G., Kpodonu J., Navarro R.A., and Geha A.S. Use of recombinant activated factor VII for bleeding following operations requiring cardiopulmonary bypass. Chest 127 (2005) 1828-1835
58. von Heymann C., Redlich U., Jain U., Kastrup M., Schroeder T., Sander M., et al. Recombinant activated factor VII for refractory bleeding after cardiac surgery-A retrospective analysis of safety and efficacy. Crit. Care Med. 33 (2005) 2241-2246
59. Raobaikady R., Redman J., Ball J.A., Maloney G., and Grounds R.M. Use of activated recombinant coagulation factor VII in patients undergoing reconstruction surgery for traumatic fracture of pelvis or pelvis and acetabulum: a double-blind, randomized, placebo-controlled trial. Br. J. Anaesth. 94 (2005) 586-591
60. Friederich P.W., Henny C.P., Messelink E.J., Geerdink M.G., Keller T., Kurth K.H., et al. Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial. Lancet 361 (2003) 201-205
61. Hendriks H.G.D., Meijer K., de Wolf J.T.M., Klompmaker I.J., Porte R.J., de Kam P.J., et al. Reduced transfusion requirements by recombinant factor VIIa in orthotopic liver transplantation: A pilot study. Transplantation 71 (2001) 402-405
62. Meijer K., Hendriks H.G., De Wolf J.T., Klompmaker I.J., Lisman T., Hagenaars A.A., et al. Recombinant factor VIIa in orthotopic liver transplantation: Influence on parameters of coagulation and fibrinolysis. Blood Coagul. Fibrinolysis 14 (2003) 169-174
63. Planinsic R.M., van der Meer J., Testa G., Grande L., Candela A., Porte R.J., et al. Safety and efficacy of a single bolus administration of recombinant factor VIIa in liver transplantation due to chronic liver disease. Liver Transpl. 11 (2005) 895-900
64. Lodge J.P., Jonas S., Jones R.M., Olausson M., Mir-Pallardo J., Soefelt S., et al. Efficacy and safety of repeated perioperative doses of recombinant factor VIIa in liver transplantation. Liver Transpl. 11 (2005) 973-979
65. Lodge J.P., Jonas S., Oussoultzoglou E., Malago M., Jayr C., Cherqui D., et al. Recombinant coagulation factor VIIa in major liver resection: a randomized, placebo-controlled, double-blind clinical trial. Anesthesiology 102 (2005) 269-275
66. Badimon J., Zaman A., Helft G., Fayad Z., and Fuster V. Acute coronary syndromes: pathophysiology and preventive priorities. Thromb. Haemost. 82 (1999) 997-1004
67. Ardissino D., Merlini P., Ariens R., Coppola R., Bramucci E., and Mannucci P.M. Tissue-factor antigen and activity in human coronary atherosclerotic plaques. Lancet 349 (1997) 769-771
68. Levi M., Peters M., and Buller H.R. Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review. Crit. Care Med. 33 (2005) 883-890
69. O'Connell K.A., Wood J.J., Wise R.P., Lozier J.N., and Braun M.M. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 295 (2006) 293-298
70. Mayer S.A., Brun N.C., Begtrup K., Broderick J., Davis S., Diringer M.N., et al. Recombinant activated factor VII for acute intracerebral hemorrhage. N. Engl. J. Med. 352 (2005) 777-785
71. ®) therapy. P & T 30 (2005) 644-658